NorthX Biologics Partners to Advance Manufacturing of Retogatein (rhGAD65) for Type 1 Diabetes Toward Commercialization
NorthX Biologics is entering a long term collaboration with Diamyd Medical and APL to support the preparation of retogatein (rhGAD65) for commercial manufacturing. Retogatein is being developed as a therapy aimed at preserving insulin producing cells in people with ...
NorthX Biologics achieves milestone GMP certification to manufacture vididencel
Mendus’ lead cell therapy product for acute and chronic myeloid leukemias Matfors, Sweden, 12 01 2025. NorthX Biologics, a leading CDMO and Swedish national innovation hub for advanced biologics, and ...
Innovation comes to life through production
Janet Hoogstraate on Sweden’s role in global biomanufacturing Sweden has built a strong foundation in life science, with world-class research environments, advanced infrastructure, and skilled professionals. In a recent interview ...
Amarna Therapeutics and NorthX Biologics finalize agreement to advance Nimvec™ AM510 gene therapy toward clinical trials for type 1 diabetes
Amarna Therapeutics, a privately held biotechnology company pioneering transformative gene therapies, today announced the formalization of an agreement with NorthX Biologics, a leading biologics manufacturing partner, to accelerate the development ...
NorthX Biologics secures significant growth investment from Signet Healthcare Partners
NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development, and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity ...
NorthX Biologics appoints Johanna Magnusson as Chief Operating Officer
Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer. With over two decades of leadership experience in ...
NorthX Biologics receives CIR accreditation to support R&D collaboration with French biotech and pharmaceutical companies
NorthX Biologics, a leading biopharmaceutical CDMO, has been officially accredited by the French Ministry of Higher Education and Research for the Crédit d’Impôt Recherche (CIR) program for the years 2025-2026. ...
NorthX Biologics appoints Patrick DePalma Senior Vice President of North American Business Development
Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Patrik DePalma as Senior Vice President of Business Development in North America. With over ...
Amarna Therapeutics partners with NorthX Biologics to advance Nimvec™ AM510 gene therapy development
Amarna Therapeutics, a privately held biotechnology company specializing in transformative gene therapies, is pleased to announce its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents ...